Suptavumab

Last updated

Suptavumab
Monoclonal antibody
Type ?
Source Human
Target respiratory syncytial virus fusion protein
Clinical data
Other namesREGN2222
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
Formula C6502H10038N1726O2020S42
Molar mass 146054.41 g·mol−1

Suptavumab (INN; [1] development code (REGN2222) is a humanized monoclonal antibody designed for the prevention of medically attended lower respiratory tract disease due to respiratory syncytial virus. [2]

This experimental drug candidate was being developed by Regeneron Pharmaceuticals Inc until it was discontinued after unsuccessful Phase III clinical trials. [3] [4]

References

  1. ↑ World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 115" (PDF). WHO Drug Information. 30 (2).
  2. ↑ Sevendal AT, Hurley S, Bartlett AW, Rawlinson W, Walker GJ (September 2024). "Systematic Review of the Efficacy and Safety of RSV-Specific Monoclonal Antibodies and Antivirals in Development". Reviews in Medical Virology. 34 (5) e2576. doi:10.1002/rmv.2576. PMID   39209729.
  3. ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Suptavumab, American Medical Association.
  4. ↑ "Regeneron to Discontinue Development of Suptavumab for Respiratory Syncytial Virus" (Press release). Regeneron. August 14, 2017.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.